Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARNESS switch study in virologically suppressed HIV-1 infection
2009-017032-41Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of atazanavir, ritonavir, raltegravir, tenofovir disoproxil fumarate and emtricitabine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of subjects with HIV-1 RNA < 40 copies/mL through Week 24. Started Jul 2011; status: completed.
02
Drugs
atazanavirritonavirraltegravirtenofovir disoproxil fumarateemtricitabine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2009-017032-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017032-41.